

28 Jun (FRI) 2024	
Venue	9F, Heart Reading Banquet, TAI Urban Resort
Time	Registration 12:30-16:00
13:50-13:55	Postgraduate Course (I)
13:55-14:20	
14:20-14:45	
14:45-15:10	
15:10-15:35	
15:35-15:55	Break
15:55-16:20	Postgraduate Course (II)
16:20-16:45	
16:45-17:10	
17:10-17:35	
17:35-17:40	

29 Jun (SAT) 2024			
Venue	Room 305	Room 304	
Time	Registration 07:30-16:00		
07:30-08:00			
08:00-08:25	Plenary Session (I) <i>Epidemiology</i>	Plenary Session (II) <i>Mechanisms of disease progression</i>	
08:25-08:50			
08:50-09:15			
09:15-09:40			
09:40-10:00	Break		
10:00-10:25	Plenary Session (III) <i>Diagnosis</i>	Plenary Session (IV) <i>Metabolic characteristics for MAFLD development</i>	
10:25-10:50			
10:50-11:15			
11:15-11:40			
11:40-11:50	Opening Ceremony		
11:50-12:20	Keynote Lecture (I)		
12:20-13:20	Luncheon Symposium (I) Gilead	Luncheon Symposium (II) Roche	
13:20-13:45	Plenary Session (V) <i>Update of HBV treatment</i>	Plenary Session (VI) <i>HCV treatment and long term outcomes</i>	
13:45-14:10			
14:10-14:35			
14:35-15:00			
15:00-15:20	Break		
15:20-15:50	Keynote Lecture (II)		
15:50-16:20	State-of-Art Lecture		
16:20-16:50	Chairman Lecture		
16:50-17:40	Evening Symposium (III) Abbvie	Evening Symposium (IV) Gilead [304A]	Evening Symposium (V) Novo Nordisk [304B]

30 Jun (SUN) 2024		
Venue	Room 305	Room 304
Time	Registration 07:00-16:00	
07:30-08:30	Presidential Award - Oral Presentation	Young Investigator Award Presentation
08:30-08:55	Plenary Session (VII) <i>Therapeutic targets and clinical trials</i>	Basic and Translational Workshop
08:55-09:20		
09:20-09:45		
09:45-10:10		
10:10-10:30	Break	
10:30-10:55	Plenary Session (VIII) <i>Novel therapy and management of obesity</i>	Basic and Translational Workshop
10:55-11:20		
11:20-11:45		
11:45-12:10		
12:10-13:10	Luncheon Symposium (VI) Novo Nordisk	Luncheon Symposium (VII) BMS
13:10-13:30	Plenary Session (IX) <i>Cross-talk between diabetologist and hepatologist</i>	Plenary Session (X) <i>Cross-talk between cardiologist and hepatologist</i>
13:30-13:50		
13:50-14:10		
14:10-14:30		
14:30-14:50		
14:50-15:10	Break	
15:10-15:35	Plenary Session (XI) <i>Current management and systemic therapies for HCC</i>	Plenary Session (XII) <i>Policy review for MAFLD</i>
15:35-16:00		
16:00-16:25		
16:25-16:50		
16:50-17:10	Closing Ceremony	

Postgraduate Course (I)		9F, Heart Reading Banquet		
<b>Moderators: Chun-Jen Liu (Taipei) / Shuichiro Shiina (Tokyo)</b>				
13:50-13:55		<b>Welcome Address and Opening</b>	<b>Pei-Jer Chen</b>	<b>Taipei</b>
13:55-14:20	PC1-1	<b>Fatty Liver Disease: The Path from Past to the future</b>	<b>Jacob George</b>	<b>Sydney</b>
14:20-14:45	PC1-2	<b>The Pathogenesis Paths from Fatty Liver to Liver Cancer</b>	<b>Takumi Kawaguchi</b>	<b>Kurume</b>
14:45-15:10	PC1-3	<b>The Links between Fatty Liver, Cardiovascular Diseases, and Diabetes</b>	<b>Kathleen E Corey</b>	<b>Boston</b>
15:10-15:35	PC1-4	<b>Experimental Studies in Fatty Liver: Animal Models and Updated Methods</b>	<b>TBD</b>	

Postgraduate Course (I)		9F, Heart Reading Banquet		
<b>Moderators: Han-Chieh Lin (Taipei) / Lai Wei (Beijing)</b>				
15:55-16:20	PC2-1	<b>The Interplay between Fatty Liver Disease and Viral Hepatitis</b>	<b>Mindie H. Nguyen</b>	<b>Palo Alto</b>
16:20-16:45	PC2-2	<b>The Lean MAFLD Patients: Characteristics and disease course</b>	<b>Jee-Fu Huang</b>	<b>Kaohsiung</b>
16:45-17:10	PC2-3	<b>The Role of Lifestyle Modifications in MAFLD/NASH</b>	<b>Vincent WS Wong</b>	<b>Hong Kong</b>
17:10-17:35	PC2-4	<b>Therapeutic perspectives of NASH</b>	<b>Philip N Newsome</b>	<b>Birmingham</b>
17:35-17:40		<b>Closing Remarks</b>	<b>Ming-Lung Yu</b>	<b>Kaohsiung</b>

**June 29, 2024 (Saturday)**

**Kaohsiung Exhibition Center**

**Plenary Session (I): Epidemiology** **Room 305**

**Moderators: Hwai-I Yang (Taipei) / TBA**

08:00-08:25	PS1-1	<b>Epidemiology of MAFLD: Global and Western Perspectives</b>	<b>Mindie H. Nguyen</b>	<b>Palo Alto</b>
08:25-08:50	PS1-2	<b>Epidemiology of MAFLD: Asia-Pacific Perspectives</b>	<b>Mei-Hsuan Lee</b>	<b>Taipei</b>
08:50-09:15	PS1-3	<b>Clinical Outcomes of Patients with MAFLD</b>	<b>Takumi Kawaguchi</b>	<b>Kurume</b>
09:15-09:40	PS1-4	<b>MAFLD in Adolescents: A Challenging Global Health Issue</b>	<b>Yen-Hsuan Ni</b>	<b>Taipei</b>

**Plenary Session (II): Mechanisms of disease progression** **Room 304**

**Moderators: Chau-Ting Yeh (Taoyuan) / Kathleen E Corey (Boston)**

08:00-08:25	PS2-1	<b>Genetic and Proteomic Architecture Predisposing to Fatty Liver Disease</b>	<b>Mohammed Eslam</b>	<b>Sydney</b>
08:25-08:50	PS2-2	<b>Multi-organ Crosstalk as Pathogenic Mechanism of Fatty Liver Disease</b>	<b>Ying-Ying Yang</b>	<b>Taipei</b>
08:50-09:15	PS2-3	<b>Deciphering Gut Microbiome Signatures for MAFLD</b>	<b>Jun Yu</b>	<b>Hong Kong</b>
09:15-09:40	PS2-4	<b>Vascular Mechanobiology in Fatty Liver Disease</b>	<b>Jordi Gracia Sancho</b>	<b>Barcelona</b>

**Plenary Session (III): Diagnosis** **Room 305**

**Moderators: Shiu-Feng Huang (Miaoli) / George Lau (Hong Kong)**

10:00-10:25	PS3-1	<b>Serum-based Biomarkers</b>	<b>TBA</b>	
10:25-10:50	PS3-2	<b>Imaging-based Non-invasive Methods for MAFLD</b>	<b>Terry Yip</b>	<b>Hong Kong</b>
10:50-11:15	PS3-3	<b>Clinical Care Pathway for Risk Stratification</b>	<b>Tawesak Tanwandee</b>	<b>Bangkok</b>
11:15-11:40	PS3-4	<b>Clinical-pathological Correlation of MAFLD/NASH</b>	<b>Matthew Yeh</b>	<b>Seattle</b>

**June 29, 2024 (Saturday)**

**Kaohsiung Exhibition Center**

**Plenary Session (IV): Metabolic characteristics for MAFLD development** Room 304

**Moderators: Cheng-Yuan Peng (Taichung) / David E Cohen (Boston)**

10:00-10:25	PS4-1	<b>The Impact of Insulin Resistance on Disease Initiation</b>	<b>Norbert Stefan</b>	<b>Tübingen</b>
10:25-10:50	PS4-2	<b>Metabolic Alterations from Steatosis to Fibrosis</b>	<b>Ming-Lun Yeh</b>	<b>Kaohsiung</b>
10:50-11:15	PS4-3	<b>Metabolic Alterations During Hepatocarcinogenesis in MAFLD and Chronic Kidney Disease</b>	<b>Ming-Hua Zheng</b>	<b>Wenzhou</b>
11:15-11:40	PS4-4	<b>Surveillance Program and Patient Management for Cardiovascular Events in MAFLD</b>	<b>Grace Lai-Hung Wong</b>	<b>Hong Kong</b>

**Opening Ceremony** Room 305

**11:40-11:50**

**Keynote Lecture (I)** Room 305

**Moderator: Wan-Long Chuang (Kaohsiung)**

11:50-12:20	KL1	<b>Emerging Metabolic Therapies for the Management of Patients with NASH</b>	<b>Stephen Harrison</b>	<b>San Antonio</b>
-------------	-----	--	-------------------------	--------------------

**Plenary Session (V): Update of HBV treatment** Room 305

**Moderators: Yun-Fan Liaw (Taipei) / Mindie H. Nguyen (Palo Alto)**

13:20-13:45	PS5-1	<b>Hepatic Steatosis and HBV Infection: Things Beyond the Causal Relationship</b>	<b>Chun-Jen Liu</b>	<b>Taipei</b>
13:45-14:10	PS5-2	<b>HDV: Old Challenges and New Chances</b>	<b>Jin-Lin Hou</b>	<b>Guangzhou</b>
14:10-14:35	PS5-3	<b>CHB Patients of the Gray Zone: To Treat or to Wait</b>	<b>Young-Suk Lim</b>	<b>Seoul</b>
14:35-15:00	PS5-4	<b>The New Hope for HBV Cure</b>	<b>Hung-Chih Yang</b>	<b>Taipei</b>

**June 29, 2024 (Saturday)**

**Kaohsiung Exhibition Center**

**Plenary Session (VI): HCV treatment and long-term outcomes**

**Room 304**

**Moderators: Chien-Hung Chen (Kaohsiung) / TBA**

13:20-13:45	PS6-1	<b>HCV Infection and Insulin Resistance: The Linkage Between the Mutual Interaction</b>	<b>Chao-Hung Hung</b>	<b>Taipei</b>
13:45-14:10	PS6-2	<b>Metabolic Impact on Hepatic Outcomes after SVR of HCV Infection</b>	<b>Chen-Hua Liu</b>	<b>Taipei</b>
14:10-14:35	PS6-3	<b>Host Immune Surveillance and Epigenetic Aspects for HCC Development after SVR</b>	<b>Meital Gal-Tanamy</b>	<b>Zfat</b>
14:35-15:00	PS6-4	<b>HCV Microelimination and Metabolic Alternation in the SVR Era</b>	<b>Chung-Feng Huang</b>	<b>Kaohsiung</b>

**Keynote Lecture (II)**

**Room 305**

**Moderator: Jia-Horng Kao (Taipei)**

15:20-15:50	KL2	<b>Research priority to advance public health responses to fatty liver disease</b>	<b>Jacob George</b>	<b>Sydney</b>
-------------	-----	--	---------------------	---------------

**State-of-Art Lecture**

**Room 305**

**Moderator: Ming-Lung Yu (Kaohsiung)**

15:50-16:20	SL1	<b>National Strategy for Eliminating Liver Diseases: From Communicable to Noncommunicable Hepatitis</b>	<b>Chen-Jen Chen</b>	<b>Taipei</b>
-------------	-----	---	----------------------	---------------

**Chairman Lecture**

**Room 305**

**Moderator: Pei-Jer Chen (Taipei)**

16:20-16:50	CL1	<b>TBA</b>	<b>Ming-Lung Yu</b>	<b>Kaohsiung</b>
-------------	-----	------------	---------------------	------------------

**June 30, 2024 (Sunday)**

**Kaohsiung Exhibition Center**

<b>Plenary Session (VII): Therapeutic targets and clinical trials</b>				<b>Room 305</b>
<b>Moderators: Jee-Fu Huang (Kaohsiung) / Takumi Kawaguchi (Kurume)</b>				
08:30-08:55	PS7-1	<b>What We Have Learned from the Failed Trials?</b>	<b>Vincent Wai-Sun Wong</b>	<b>Hong Kong</b>
08:55-09:20	PS7-2	<b>Pharmacotherapeutic Trials Achieving NASH Resolution and Beyond</b>	<b>Ming-Ling Chang</b>	<b>Taoyuan</b>
09:20-09:45	PS7-3	<b>Weight-lowering Drugs in Clinical Trials</b>	<b>TBA</b>	
09:45-10:10	PS7-4	<b>The Unmet Needs and the Endpoints of NASH Clinical Trials</b>	<b>Philip N Newsome</b>	<b>Birmingham</b>

<b>Basic and Translational Workshop (I)</b>				<b>Room 304</b>
<b>Moderators: Yan-Hwa Wu Lee (Hsinchu) / Chia-Ho Shih (Taipei)</b>				
08:30-08:55	BTW1-1	<b>Animal Model for Associations between Hormones and Metabolic-Associated Fatty Liver Disease</b>	<b>Shiou-Hwei Yeh</b>	<b>Taipei</b>
08:55-09:20	BTW1-2	<b>Advance in the Methodology for Vasculopathy in MAFLD</b>	<b>Jordi Gracia Sancho</b>	<b>Barcelona</b>
09:20-09:45	BTW1-3	<b>Advances of Organoids in MAFLD</b>	<b>Yun-Shen Chan</b>	<b>Guangzhou</b>
09:45-10:10	BTW1-4	<b>Energy Expenditure in Fatty Liver</b>	<b>David E Cohen</b>	<b>Boston</b>

<b>Plenary Session (VIII): Novel therapy and management of obesity</b>				<b>Room 305</b>
<b>Moderators: Chun-Yen Lin (Taoyuan) / Diana A. Payawal (Manila)</b>				
10:30-10:55	PS8-1	<b>Lifestyle Modification for Obesity and Nutrition Recommendation</b>	<b>Meng-Chuan Huang</b>	<b>Kaohsiung</b>
10:55-11:20	PS8-2	<b>Crucial Role of Exercise in Treatment for Obesity</b>	<b>Sen-Fang Huang</b>	<b>Hualien</b>
11:20-11:45	PS8-3	<b>Therapeutic Approach for Obesity</b>	<b>Stephen Harrison</b>	<b>San Antonio</b>
11:45-12:10	PS8-4	<b>Endoscopic and Surgical Treatments for Obesity</b>	<b>Chi-Ming Tai</b>	<b>Kaohsiung</b>

**June 30, 2024 (Sunday)**

**Kaohsiung Exhibition Center**

<b>Basic and Translational Workshop (II)</b>				<b>Room 304</b>
<b>Moderators: Mei-Hwei Chang (Taipei) / David E Cohen (Boston)</b>				
10:30-10:45	BTW2-1	<b>Metabolomics in Liver Disease</b>	<b>Ching-Hua Kuo</b>	<b>Taipei</b>
10:45-11:00	BTW2-2	<b>Role of Apolipoprotein J in the Progression of MAFLD</b>	<b>Kung-Chia Young</b>	<b>Tainan</b>
11:00-11:15	BTW2-3	<b>Resolution of liver fibrosis in NAFLD</b>	<b>Kuei-Chuan Lee</b>	<b>Taipei</b>
11:15-11:30	BTW2-4	<b>An Omega-6 PUFA Derived Oxilipin Prevents Diet-induced Obesity, Insulin Resistance, and Steatohepatitis in Mice</b>	<b>Yi-Cheng Chang</b>	<b>Taipei</b>
11:30-11:45	BTW2-5	<b>Cardiac fibrosis in NASH mice treated with GLP-1 RA and pioglitazone</b>	<b>Wei-Ting Chang</b>	<b>Kaohsiung</b>
11:45-12:00	BTW2-6	<b>Identification of genetic alterations during fibrogenesis in MAFLD</b>	<b>Chia-Hung Yen</b>	<b>Kaohsiung</b>

<b>Plenary Session (IX): Cross-talk between cardiologist and hepatologist</b>				<b>Room 305</b>
<b>Moderators: Wen-Jone Chen (Taipei) / Yen-Wen Wu (Taipei) / Pin-Nan Cheng (Tainan)/ Sheng-Nan Lu (Kaohsiung)</b>				
13:10-13:30	PS9-1	<b>CV Risk and Outcomes</b>	<b>Ki-Chul Sung</b>	<b>Seoul</b>
13:30-13:50	PS9-2	<b>Interplay among MAFLD, CV and DM</b>	<b>Joseph Pappachan</b>	<b>Preston</b>
13:50-14:10	PS9-3	<b>Surveillance Program and Patient Management for Cardiovascular Events in MAFLD</b>	<b>Grace Lai-Hung Wong</b>	<b>Hong Kong</b>
14:10-14:30	PS9-4	<b>Current Guidance of MAFLD-CVD: Cardiologist's View</b>	<b>Yen-Wen Wu</b>	<b>New Taipei City</b>
14:30-14:50	PS9-5	<b>Current Guidance of MAFLD-CVD: Hepatologist's View</b>	<b>Pin-Nan Cheng</b>	<b>Tainan</b>



**June 30, 2024 (Sunday)**

**Kaohsiung Exhibition Center**

**Plenary Session (X): Cross-talk between diabetologist and hepatologist Room 304**

**Moderators: Chien-Ning Huang (Taichung) / Chih-Yuan Wang (Taipei) / Huey-Ling Chen (Taipei) / Rong-Nan Chien (Taoyuan)**

13:10-13:30	PS10-1	<b>The Impact of MAFLD on DM</b>	<b>Horng-Yih Ou</b>	<b>Tainan</b>
13:30-13:50	PS10-2	<b>The Impact of DM on MAFLD</b>	<b>Kathleen E Corey</b>	<b>Boston</b>
13:50-14:10	PS10-3	<b>Recent Advances in Anti-diabetes Drugs</b>	<b>Yi-Sun Yang</b>	<b>Taichung</b>
14:10-14:30	PS10-4	<b>Current Guidance of MAFLD-DM: Endocrinologist's View</b>	<b>Chih-Yuan Wang</b>	<b>Taipei</b>
14:30-14:50	PS10-5	<b>Current Guidance of MAFLD-DM: Hepatologist's View</b>	<b>Mohamed Rosmawati</b>	<b>Kuala Lumpur</b>

**Plenary Session (XI): Current management and systemic therapies for HCC Room 305**

**Moderators: Chai-Yen Dai (Kaohsiung) / Shuichiro Shiina (Tokyo)**

15:10-15:35	PS11-1	<b>The Impact of Steatosis on HCC Treatment</b>	<b>Yi-Hsiang Huang</b>	<b>Taipei</b>
15:35-16:00	PS11-2	<b>NAFLD-driven HCC: Safety and Efficacy of Current Treatment Options</b>	<b>Teerha Piratvisuth</b>	<b>Songkhla</b>
16:00-16:25	PS11-3	<b>Systemic Treatment of Non-viral HCC: An Asian Perspective</b>	<b>Stephen L Chan</b>	<b>Hong Kong</b>
16:25-16:50	PS11-4	<b>Novel Systemic Treatment for HCC</b>	<b>Ann-Lii Cheng</b>	<b>Taipei</b>



**June 30, 2024 (Sunday)**

**Kaohsiung Exhibition Center**

<b>Plenary Session (XII): Policy review for MAFLD</b>				<b>Room 304</b>
<b>Moderators: Pei-Jer Chen (Taipei) / Masao Omata (Tokyo)</b>				
15:10-15:25	PS12-1	<b>Policies and Strategy in MAFLD: West Pacific View</b>	<b>Chun-Jen Liu</b>	<b>Taipei</b>
15:25-15:40	PS12-2	<b>Policies and Strategy in MAFLD: East Asia View</b>	<b>Jian-Gao Fan</b>	<b>Shanghai</b>
15:40-15:55	PS12-3	<b>Policies and Strategy in MAFLD: South Pacific and Polynesian View</b>	<b>Jacob George</b>	<b>Westmead</b>
15:55-16:10	PS12-4	<b>Policies and Strategy in MAFLD: South-East Asia View</b>	<b>Wah-Kheong Chan</b>	<b>Kuala Lumpur</b>
16:10-16:25	PS12-5	<b>Policies and Strategy in MAFLD: South Asia View</b>	<b>Shiv K. Sarin</b>	<b>New Delhi</b>
16:25-16:40	PS12-6	<b>Epidemiology, genotype distribution, prognosis and treatment of Hepatitis C, and HCC in Mongolia</b>	<b>Oidov Baatarkhuu</b>	<b>Ulaanbaatar</b>
16:40-16:50		<b>Panel Discussion &amp; Announcement</b>		
<b>Closing Ceremony</b>				<b>Room 305</b>
<b>17:15-17:30</b>				